Pharmafile Logo
Pharmafocus logo
Advanced Search

HIV

Showing 15 posts of 194 posts found.

1920px-hiv-budding-color

GSK’s two drug HIV regimen effective when administered every two months

August 22, 2019
Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression

GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News
1920px-hiv-budding-color

Scientists use duoCAR-T therapy to fight HIV

August 9, 2019
Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma

Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …

News
gilead-sciences

Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

August 8, 2019
Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …

News
1920px-hiv-budding-color

MSD trials long lasting PrEP implant for preventing HIV

July 23, 2019
Research and Development AIDS, HIV, MSD, PrEP, pharma

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

News
1920px-hiv-budding-color

ViiV Healthcare’s two drug HIV therapy beats Gilead’s three drug treatment in Phase 3 trial

July 10, 2019
Research and Development AIDS, Dovato, GSK, Gilead, HIV, ViiV, pharma

Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint …

News
gsk_china_2_2_0_1

GSK opens new manufacturing plants in Singapore

July 5, 2019
Manufacturing and Production Asia, HIV, Singapore, anaemia, facilities, manufacturing, pharma

British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore. The UK firm has also expanded facilities at its …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

July 5, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma

The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to …

News
landing-hero-images1

ViiV’s Dovato approved in Europe as treatment option for HIV-1

July 3, 2019
Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …

News
1920px-hiv-budding-color

Researchers use gene-editing tool CRISPR to cure mice of HIV

July 3, 2019
Research and Development AIDS, HIV, Nature Communications, crispr, mice, pharma

American scientists have been able to combine a new form of antiretroviral therapy (ART) with gene editing tool CRISPR/Cas9 to …

News
condom-3197506_960_720

Cases of sexually transmitted infections on the rise in England, data shows

June 5, 2019
Research and Development HIV, STDs, STIs, pharma PrEP, public health

Cases of sexually transmitted infections (STIs) are on the rise, according to new data from Public Health England. There were …

News
1920px-hiv-budding-color

KCL study could lead to improved vaccinations against STIs

May 23, 2019
Research and Development HIV, HSV, STIs, herpes, immune system, std

New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs). Researchers at …

News
46438135835_a0bd733416_z

Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada

May 17, 2019
Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma

On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …

News
gilead-sciences

Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says

May 15, 2019
Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs

Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …

News

Clinical trial will test long acting HIV injection

May 10, 2019
Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …

News

Latest content

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023